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ABSTRACT 
Introduction: Mild cognitive impairment (MCI) is a term used to describe a level of 
decline in cognition which is seen as an intermediate stage between normal ageing 
and dementia, and which many consider to be a prodromal stage of neurodegeneration 
that may become dementia. That is, it is perceived as a high risk level of cognitive 
change. The increasing burden of dementia in our society, but also our increasing 
understanding of its risk factors and potential interventions, require diligent 
management of MCI in order to find strategies that produce effective prevention of 
dementia.  
Aim: To update knowledge regarding mild cognitive impairment, and to bring 
together and appraise evidence about the main features of clinical interest: definitions, 
prevalence and stability, risk factors, screening, and management and intervention. 
Methods: Literature review and consensus of expert opinion. Results and conclusion: 
MCI describes a level of impairment in which deteriorating cognitive functions still 
allow for reasonable independent living, including some compensatory strategies. 
While there is evidence for some early risk factors, there is still a need to more 
precisely delineate and distinguish early manifestations of frank dementia from 
cognitive impairment that is less likely to progress to dementia, and furthermore to 
develop improved prospective evidence for positive response to intervention. An 
important limitation derives from the scarcity of studies that take MCI as an endpoint. 
Strategies for effective management suffer from the same limitation, since most 
studies have focused on dementia. Behavioural changes may represent the most cost-
effective approach. 
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Introduction 
Cognitive decline defines the phenotypic translation of the deterioration affecting 
neuronal networks across senescence. Mild cognitive impairment (MCI) materialises 
the stage previous to dementia, the final station. The increasing burden of dementia in 
our society requires a diligent management of MCI in order to find strategies aiming 
at effective prevention.   
AIM 
To update the knowledge about cognitive decline and to analyse evidence about the 
main features of clinical interest. 
Methods 
Literature review and consensus of expert opinion. 
Results and conclusion 
MCI comprises a milder status in which deteriorating cognitive functions still allow 
for reasonable independent living. There is interest in identifying indicators to early 
delineate the forms constituting initial manifestations of unavoidable dementia. Risk 
factors and adequate assessment are being investigated in epidemiological studies, but 
high-level evidence is still insufficient. An important limitation derives from the 
scarce number of studies taking MCI as an endpoint. Strategies for effective 
management suffer from the same limitation, since most studies have focused on 
dementia. Behavioural changes may represent the most cost-effective approach.  
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1. Introduction and concept 
The term Mild Cognitive Impairment (MCI) was introduced as a clinical entity over 
twenty years ago. Initially, Reisberg and colleagues [1] used this term to describe 
patients who were at the intermediate stage between normal ageing and dementia 
state.  Later, a set of diagnostic criteria was defined [2]. These diagnostic criteria 
included abnormal memory function for the person’s age and, in association, memory 
complaints, as well as normal general cognitive function and normal activities of daily 
living (ADL). In addition, the absence of dementia was inferred, although it was 
suggested that MCI can constitute a prodromal form of Alzheimer´s Disease (AD) [3]. 
More recently, the investigation from clinical, pathological, genetic, imaging and 
epidemiological perspectives suggests that MCI should be expanded to include other 
cognitive domains such as executive function or visuospatial skills [4-7]. 
Simultaneously, memory impairment was no longer considered a necessary diagnostic 
condition. The criteria related to preservation of independence in functional abilities, 
and to the absence of dementia, were maintained. 
According to this new approach [5], MCI was defined by a decline in cognitive 
functioning that is greater than would be expected for the patient's age and 
educational background and that goes beyond normal changes seen in ageing. This 
decline from a previous level can include a variety of cognitive domains, including 
learning and memory, complex attention, executive functions, language, perceptual-
motor domain and social cognition [8], although it is common that decline manifests 
in a single domain only. Changes in cognitive functioning should be serious enough 
to be noticed either by the individuals experiencing them, by other people who know 
This article is published as: Apostolo, J, Holland, C, O’Connell MDL, Feeney J, Tabares-Seisdedos, R, 
Tadros,G., Campos, E,  Santos, N. Robertson, DA, Marcucci M, Varela-Nieto, Crespo-Facorrom B, Vieta, E. 
Navarro-Pardo, E, Selva-Vera G, Balanzá-Martínez V, Cano, A (2016) Mild cognitive decline. A position 
statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy 
Ageing (EIPAHA) Maturitas http://dx.doi.org/10.1016/j.maturitas.2015.10.008 
 
 
9 
9 
the patient well or by a skilled clinician in an appropriate clinical context [5]. For 
example, impairment in memory can be evidenced by forgetting of important events 
such as appointments or social engagements, trouble remembering the names of 
people met recently, word-finding difficulties, trouble remembering the flow of a 
conversation or the thread of books or movies and an increased tendency to misplace 
things. While these cognitive changes should not be severe enough to interfere with 
ADL, complex functional tasks, for example, interpretation of instructions, planning 
subsequent activities or making decisions, may require the engagement of 
compensatory strategies by the individual [8]. 
1.1 Amnestic MCI versus non-amnestic MCI 
Longitudinal studies have indicated that MCI can evolve into different forms of 
dementia and that this evolution depends on the nature and extent of cognitive 
impairments experienced in the transitory stage [4]. In order to define better the 
determinants for making diagnostic decisions, and provide more targeted 
interventions, differentiation between MCI with (amnestic MCI, a-MCI) or without 
(non-amnestic MCI, na-MCI) decline in the memory domain has been proposed. 
Additionally, it is considered relevant to specify whether the diminishing of 
functioning involves only one cognitive domain or more [4,9]. 
1.2 Mild Cognition Impairment in DSM-5 perspective 
The clinical criteria for MCI are also considered in The Diagnostic Statistical Manual-
5 (DSM-5) [10], although, in this case, a term used for diagnostic purposes is Mild 
Neurocognitive Disorder (mild NCD). Mild NCD is included together with Major 
Neurocognitive Disorders (major NCD) in the general category of Neurocognitive 
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Disorders (NCD).  
The common feature of NCD is the absence of cognitive impairment at the moment of 
birth or during early life. Thus, evidence of cognitive decline, necessary to complete 
the diagnosis, should be based on the previous level of performance. Importantly, the 
decline in cognitive domains should not appear in the context of delirium or result 
from other mental disease. This clarification is pertinent, because NCD may result 
from aetiologies different to neurocognitive disorders. For example, a person with 
suspected AD may be classified as having mild NCD due to AD. Other causes may be 
vascular, traumatic, or others [10].  
Conceptual definitions of MCI have changed over time. Despite intense effort to 
clarify neuropsychological and clinical profile of this condition, there is still lack of 
consensus about its neuropathological substratum. It is also necessary to harmonize 
definitions and labels across working groups and disciplines. 
 
2. Prevalence and stability 
Reported prevalence of MCI varies, with annual incidence rate ranging from 5.5 to 
7.7 per cent of persons aged 60 or over [11], and Plassman et al [12] estimating 22% 
of people aged over 71 as having cognitive impairment but not dementia. In terms of 
the concept of MCI as an intermediate phase of AD [6], it has been demonstrated that 
15-41% of MCI cases per year progress to AD or other dementias [13-15]. For 
example, in a four year study, Lonie et al [16] found a mean annual conversion rate of 
11% when assessed using the Addenbrooke’s Cognitive Examination criteria, 
although other authors suggest this may be less (5.8%) [17]. 
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Conversely, studies have also shown that up to 44% of patients with MCI return to a 
non-MCI diagnosis a year later [14,18] suggesting that it can be viewed as unstable. 
For example, in an eight year longitudinal study, Anstey et al [19] found that 45% of 
diagnoses were unstable for their group of young-old participants aged 62-64 at 
baseline. Thus MCI could be viewed as a transient and high risk phase, and 
interventions to promote improved health or cognitive functioning could be 
particularly pertinent for this group. However, these data also indicate that diagnosis 
or screening of MCI may still be imprecise. 
 
3. Risk factors 
Studies on risk factors for MCI suffer from the limitation that the cohorts are almost 
always contaminated by those cases that are already at an early stage of dementia but 
do not yet fulfil the necessary criteria for a dementia diagnosis. Of course, this is 
unavoidable on account of the inherent difficulty in distinguishing between cases of 
MCI and those individuals who are suffering from mild dementia. It follows then, that 
there is a high interest in detecting factors that predict membership of the second 
group, for example, the APOE4 allele, and there is a large literature on risk factors 
which examines that issue. This “contamination” also raises the philosophical 
question of whether MCI is in itself a different entity to early-stage dementia, or 
whether all cases of MCI are in fact preliminary dementias, with diverse aetiologies 
and varying prognoses depending on the potential for disease progression.  
Furthermore, there are also inconsistencies in how different studies define MCI when 
attempting to determine risk factors. Many studies simply refer to cognitive decline or 
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cognitive impairment, usually operationalised as a decline in objective cognitive 
functioning over time, or falling below a threshold score at a single point in time. 
Finally, there is the related issue of the instability of an MCI diagnosis, as many cases 
considered as such no longer meet the criteria at follow-up assessment. These 
limitations and inconsistencies undoubtedly hamper cross-study comparisons and 
limit the generalisability of the findings from any single study. This highlights the 
importance of meta-analysis and related tools in determining risk factors that are 
robust to these variations until such time as MCI as a diagnostic entity is more 
consistently defined and characterised. 
The process leading to MCI is undoubtedly complex, involving multiple, sometimes 
interrelated, risk factors. There is an expanding literature on the topic. This section 
will summarise current knowledge on some of the main factors identified with 
particular reference to studies focusing on MCI as an outcome. An overview of these 
risk factors is provided in Table 1. 
3.1 Demographic factors 
Higher age is the best known demographic risk factor, particularly being over the age 
of 85 [20]. However, estimating the true extent of the association has been 
problematic, in part because age-corrected normative data for cognitive tests are 
frequently used to identify individuals with probable MCI. The influence of gender on 
the development of MCI is not yet clear. Some studies have demonstrated no gender 
difference [21], others that males have higher prevalence [22], and others that women 
have a greater risk of MCI [20]. 
3.2 Genetic factors 
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In terms of genetic markers, the only widely accepted risk factor is the presence of the 
APOE4 allele, which is for Alzheimer’s dementia [6]. A recent cross-sectional 
analysis from the Framingham Heart study found an association between APOE4 and 
MCI, particularly among participants aged 65 and older [23]. Similarly, a study of 46 
Cuban MCI patients and 28 controls found the frequency of the APOE4 allele to be 
10 times higher in patients compared to controls, although the absolute frequency in 
patients was only 20% [24]. 
3.3 Cardiovascular risk factors  
A large amount of clinical, pathologic and epidemiological evidence supports the 
association between cardio-metabolic risk factors and cognitive impairment, from its 
mild expression to overt dementia, including both vascular cognitive impairment [25] 
and AD, independently of the occurrence of stroke. 
Diabetes mellitus, but also higher glucose levels and insulin resistance in non-diabetic 
individuals, have been linked to a higher risk of cognitive impairment [26-28]. Higher 
baseline blood pressure [29], cholesterol levels [30], weight and body mass index [31] 
are associated with faster decline in cognitive performance over time, either when 
studied individually, clustered in metabolic syndrome or summed up in cardiovascular 
risk scores [32,33]. However, the available evidence on the association between the 
traditional vascular risk factors and cognitive impairment is not always consistent and 
might appear controversial if some elements are not considered, for example, age at 
which the risk factor is detected and the study design are important. Longitudinal 
studies in cognitively healthy midlife participants have found the strongest 
associations [34,35]; however, this may be complicated by the presence of a 
This article is published as: Apostolo, J, Holland, C, O’Connell MDL, Feeney J, Tabares-Seisdedos, R, 
Tadros,G., Campos, E,  Santos, N. Robertson, DA, Marcucci M, Varela-Nieto, Crespo-Facorrom B, Vieta, E. 
Navarro-Pardo, E, Selva-Vera G, Balanzá-Martínez V, Cano, A (2016) Mild cognitive decline. A position 
statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy 
Ageing (EIPAHA) Maturitas http://dx.doi.org/10.1016/j.maturitas.2015.10.008 
 
 
14 
14 
confounding effect of the decrease of cholesterol levels and weight that might 
accompany an unhealthy ageing process and particularly dementia in older adults 
[36]. The duration of exposure to vascular risk also likely plays a role [37].  
For certain vascular risk factors, the relationship might not be monotonic. For 
example, a U-shaped relationship between blood pressure and cognitive decline has 
been suggested by several studies (e.g. [38]). Repeated episodes of cerebral 
hypoperfusion associated with orthostatic hypotension are as likely to be deleterious 
as chronic hypertension [39]. This might be one reason the data on the effect of 
hypoglycemic therapies, antihypertensive drugs, or statin use on the risk of cognitive 
impairment are not conclusive [40,41]. Finally, effect of vascular risk factors might be 
modified by the interaction with other risk factors, or with different cognitive disease 
subtypes, which the existing limited classification criteria might not ascertain.  
Several cross-sectional and longitudinal studies have also shown that patients with 
atrial fibrillation (chronic or paroxysmal) present with worse cognitive and functional 
performance, and worse trajectories of cognitive test score over time, compared with 
those in sinus rhythm, even in absence of clinical stroke [42]. Silent cerebral cardio-
embolic infarctions may represent the pathological substrate [43]. Mainly because of 
methodological difficulties, there is no clear evidence regarding a possible protective 
effect of anticoagulant agents [44]. 
Encouragingly, most of the major vascular risk factors are modifiable, offering 
attractive opportunities for disease prevention. For the above mentioned reasons, the 
timing of any intervention is likely to be crucial to favour success and avoid any 
iatrogenic harm.  
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3.4 Sensory factors 
Sensory deficits are common in older adults with approximately one-third of adults 
aged 65 and over affected by hearing loss [45]. Oxidative stress, inflammation and 
neurological degeneration have been implicated in the development of hearing loss, 
retinal, macular and olfactory degeneration – potentially leading to a generalised 
sensory impairment [46]. This may impact on an individual’s independence and 
ability to interact with their environment, with implications for cognitive function. 
Hearing impairment in particular has been related to physical frailty and poorer 
mental health [47,48]. The mechanisms linking sensory deficits and cognitive 
function are still unclear. 
 
3.4 Behavioural factors 
Over the last decade in particular, there has been considerable interest in physical 
activity as both a modifiable risk factor and an interventional tool for preventing or 
ameliorating cognitive impairment. Meta-analyses of prospective studies have shown 
that physical activity, in particular moderate activity, is associated with a lower risk of 
cognitive decline [49,50]. Recently, studies have started to examine MCI as a distinct 
outcome but the relationship between physical activity and incident cognitive 
impairment rather than dementia remains somewhat equivocal [51,52]. However, it is 
clear that exercise is beneficial for cognitive health and thus represents a very good 
modifiable risk factor to target. A limitation of many investigations in this area to date 
is the reliance on self-report instruments to ascertain level of physical activity, which 
are susceptible to recall and other biases. It is encouraging, however, that studies 
This article is published as: Apostolo, J, Holland, C, O’Connell MDL, Feeney J, Tabares-Seisdedos, R, 
Tadros,G., Campos, E,  Santos, N. Robertson, DA, Marcucci M, Varela-Nieto, Crespo-Facorrom B, Vieta, E. 
Navarro-Pardo, E, Selva-Vera G, Balanzá-Martínez V, Cano, A (2016) Mild cognitive decline. A position 
statement of the Cognitive Decline Group of the European Innovation Partnership for Active and Healthy 
Ageing (EIPAHA) Maturitas http://dx.doi.org/10.1016/j.maturitas.2015.10.008 
 
 
16 
16 
using objective measurements of activity and measured improvements in 
cardiovascular fitness are coming to the fore [53].  
Evidence that smoking is a risk factor for dementia is mounting. Much of the 
evidence supports an increased risk for current smokers when compared with 
individuals who have never smoked, with the risk attributable to previous smoking 
less clear [54]. To date, investigations of smoking and incident MCI specifically, 
rather than dementia, have been lacking. However, studies examining the impact of 
current smoking on subsequent change in cognitive performance suggest that current 
smoking is associated with cognitive decline in individuals without dementia [55,56].  
Many studies have investigated the association between alcohol consumption and risk 
of cognitive impairment. In the main, the body of evidence supports a reduced risk of 
dementia for light to moderate drinkers compared with abstainers and heavy drinkers 
[57,58]. Fewer studies have focused on MCI only; among those available, the results 
have been more mixed, with some studies reporting an U-shaped relationship between 
alcohol intake and MCI risk [59] and others finding no protective effect of alcohol 
intake at any level [11]. However, the concentration and type of alcohol consumed as 
well as the frequency of intake varies between studies, making cross-comparisons 
somewhat challenging. More research on this is warranted, in particular where MCI 
as the outcome is concerned. 
3.5 Psychosocial factors 
Lower education has been associated with higher risk of MCI [60] and, unlike age and 
gender, there is the potential to modify this risk factor at the population level, so it 
presents an attractive target for risk reduction. There is evidence that education may 
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alter neurobiological substrates to change the brain, by increasing grey matter volume 
and through continuous activation of the noradrenergic system [61-63].  There are 
however, some important points to note when endeavouring to interpret 
epidemiological data on education and risk of MCI:  (i) some assessment measures 
(e.g. MMSE) are not sensitive enough to detect mild changes in cognition in highly 
educated people [64]; (ii)  according to DSM 5, “norms for neuropsychological 
testing tend to be available only for broad populations, and thus they may not be 
easily applicable to individuals with less than high school education or those being 
evaluated outside their primary language or culture”; (iii) education level may affect 
the level of concern, awareness and reporting of cognitive symptoms, and therefore 
has the potential to influence the likelihood of diagnosis. 
A growing body of literature has found that it is not purely formal education that may 
protect against cognitive decline but mental stimulation in its many forms, including 
social and cognitive engagement. One of the first studies to show the potentially 
protective effects of social engagement on cognitive function was that by Bennett et 
al. who found that older adults with high social networks had higher levels of 
cognitive function regardless of the level of AD pathology present in their brains at 
autopsy [65].  This finding has been replicated in other samples (e.g. [66]). However, 
other studies suggest that high social networks may be concomitant with high 
cognitive function rather than protective [67]. It is possible that the quality of social 
engagement is more important than the size of social networks in protecting against 
cognitive decline [68]. Furthermore, a recent meta-analysis on the association 
between social relationship and risk of dementia found that social network size and 
satisfaction with social networks were not associated with cognitive decline but low 
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social participation and less frequent social contact were [69].  Although an 
encouraging area of investigation, more research into the exact nature of the benefit 
conferred by social relationships on cognitive health is needed. 
Prosocial behaviour may also protect against cognitive impairment by supporting 
mental health. Among the different types of psychiatric illness, depression has been 
most consistently associated with MCI and dementia in the literature. However, the 
causal nature of the relationship has often been called into question. It has been 
argued that the three may sit along a continuum, as clinical manifestations of the same 
underlying neurodegenerative process [70].  There is, nonetheless, considerable 
support for depression as a risk factor for MCI; for example, a recent study by Chung 
and colleagues found an association between lifetime history of major depression and 
amyloid beta deposition in individuals with MCI, regardless of current depressive 
symptoms [71]. 
4. Screening and assessment  
Because of the potential malleability, and the opportunity for intervention, the role of 
screening and assessment for MCI is paramount. It is commonly thought that 
population based screening for cognitive impairments would be unacceptable to 
individuals and unfeasible to healthcare systems [72], although studies that explore 
whether there is evidence for such attitudes are not found in the literature, and would 
be a useful contribution. However, the increasing understanding of risk factors and 
opportunities for prevention and treatment in the early stages of cognitive decline 
offer promising avenues for reducing the frequency of dementia in our populations. 
Clarifying whether earlier screening can be operationalised and simplified for routine 
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clinical use is therefore vital. 
4.1 Relationship between diagnostic criteria and appropriate assessment 
Key criteria for diagnosing MCI were defined by Petersen et al., [2] as (i) a memory 
complaint (ii) normal activities of daily living (ADL) (iii) normal general cognitive 
function (iv) abnormal memory for age (v) no dementia. These criteria have since 
been expanded to include the concept of decline in functions other than memory so 
that an amnestic and non-amnestic category of MCI are used (see 1. Introduction and 
concept). However, studies have also indicated a differentiation between basic 
activities of daily living (BADL) and instrumental activities of daily living (IADL) 
such that while people with MCI do not show any BADL deficits (feeding, bathing or 
dressing oneself etc), IADL (taking care of one’s own finances, medication, shopping, 
etc) can be impaired before the actual onset of dementia [73,74].  
In that context, Winblad et al [75], in an international consensus report, suggested that 
the definition should be amended to “preserved BADL and/or minimal impairment in 
complex instrumental functions”, therefore allowing for discrete IADL deficits in 
MCI. This turns out to be useful. A review and meta-analysis by Jekel et al [76] 
indicated that deficits in IADL were very commonly found in people diagnosed with 
MCI, but with specific emphasis on those IADL that demanded higher cognitive 
skills. For example, deficits in managing finance were almost universally found. 
Given that MCI patients with reduced IADL seem to be more likely to convert to 
dementia [77-80], any screening and assessment needs to include IADL as a central 
part, not just because of its predictive utility, but also because of its use in enabling 
the focused planning of support or rehabilitation strategies to enable continued 
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independence. Indeed, Jekel et al [76] recommend the use of IADL measures that are 
specifically designed for MCI, that include performance measures rather than self-
declaration or even informant rating, and, in the reality of a short time scale for 
assessment in a clinical situation, focus on those IADL known to differentiate, that is, 
those with higher cognitive demand such as financial management. Increasingly, in 
terms of independence in today’s systems, the ability to use technology such as on-
line banking or social benefits applications are recommended to be included in new 
formulations of IADL assessment where appropriate. 
Thus in addition to the standard expected cognitive screening, evidence for factors 
that predict progressive decline, as well as definitions, imply the use of appropriate 
IADL screening, screening for depression, and screening/medication treatment review 
for co-morbidities. 
4.2 Assessing cognitive impairment 
4.2.1 Mini-Mental State Exam (MMSE) 
 Probably the best known brief screening for cognitive impairment internationally is 
the Mini-Mental State Exam (MMSE [81]). Validated in many countries and 
languages, this is perhaps the most widely used in both clinical and community 
settings. It has many weaknesses as the score is affected by level of education and 
intelligence, inability to monitor change in severe cases, lack of executive functions 
testing and absence of consideration of cultural differences. Therefore, it is acceptable 
only as an initial indicator that a person may need further investigation.  
The MMSE has been evaluated in a variety of settings, with a meta-analysis by 
Mitchell [82] suggesting that its sensitivity and specificity varies according to the 
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population, and reported very limited utility of this measure for diagnosing MCI. In a 
Cochrane review [83] specifically examining the utility of the MMSE for predicting 
the likelihood of dementia amongst people with MCI, the authors concluded that it 
was not recommended for this purpose, although with the caveat that decline in the 
score over repeated testing may prove useful. Use of a “delayed verification” period 
(usually used in diagnosing dementias, for example, to rule out temporary causes of 
impairment) would support such validation. Furthermore, given that executive 
functioning is required to control the allocation of attention and is specifically 
implicated in compensatory function in situations of mild impairment (e.g. [84]), and 
it is impaired in a significant proportion of MCI patients [85], measures such as the 
MMSE which do not include an executive component would be inappropriate for 
assessment of MCI. 
4.2.2 Other screening instruments 
In a review of screening in dementia and cognitive impairment, Cullen et al [86] 
counsel against recommendations for the universal adoption of specific screening 
measures in different settings and for different purposes, given that a “one size fits 
all” approach is unlikely to be appropriate. Tools designed for indicating dementia 
may simply not be appropriate on their own for indicating MCI.  
In a review of screening measures, Lonie, Tierney and Ebneier [87] presented 
analyses of fifteen screening assessments in terms of their use for identifying MCI. 
Full descriptions of the sensitivities and specificities can be found in that reference, 
but it was clear that clinically relevant period re-test (6 or 12 months) scores, so 
important for this population, were absent. Most provided cut-off values to 
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differentiate MCI from normal ageing (the exception was the CERAD, Consortium to 
Provide a Registry for Alzheimer’s Disease) and one provided demographic 
adjustment equations (the Montreal Cognitive Assessment, MoCA [88]). The 
Addenbrookes Cognitive Examination- Revised (ACE-R) [89] and the DemTect [90] 
had been validated with non-AD dementias and MCI, but most had not. Only four of 
the fifteen measures were found to have adequate sensitivity and specificity values 
(≥79%) for distinguishing MCI from normal healthy age matched controls: these were 
the ACE-R, DemTect, MoCA and the Memory Alteration Test (M@T, [91]), 
although of these, only the ACE-R and the MoCA covered all the recommended 
categories of cognitive function. Lonie et al [87] reported that adequate sensitivity 
values, to distinguish a wider range of possible early dementias, were only available 
for the ACE-R.  
However, none of these measures reported specificity values for depression that, as 
commented above, may be associated with MCI [70,92]. Furthermore, none of the 
measures included any assessment of speed of processing or reaction time, or of inter-
individual variability, with change in both sets of measures being increasingly 
recognised as predictors of cognitive decline [93,94].  
The advent of tablet versions will make the availability of such assessments much 
more possible in clinical and community settings. Reliability and predictive validity 
of the measures did not appear to be available in the studies reviewed, although Lonie 
et al [87] went on to provide this for the ACE-R. 
Table 2 presents these assessment tests and their main features. 
4.2.3 The issue of low literacy, education and culture 
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Finally, many of these assessments are of very limited use in populations with very 
low education and literacy levels, and despite an awareness that dementias are more 
common amongst people with low education and that this decreases the chance of 
detecting the earlier stages of dementia or MCI [95], there are few evidenced 
strategies to deal with this concern. Reviews (e.g.[96]) recommend using a 
combination of screening and informant information, with an emphasis on reports 
from a person who knows the patient well, comparing the person’s present and past 
performance.  
Of the screening tools used, the most commonly employed were specific items such 
as verbal fluency or immediate and delayed recall of verbal material. Most included 
subjective memory complaint. One study delineated education adjusted cut-offs for 
the MoCA which may be useful for similar samples [97], whereas others 
recommended informant/interview based measures such as the Clinical Dementia 
Rating (CRD) scale or the Alzheimer’s disease 8 questionnaire (AD8 [98]).  
The assessment of cognitive decline in patients from minority ethnicities where they 
are being assessed in a language which is not their first language, and maybe where 
social expectations for older people are low, remains a major barrier for clinical 
practice [99].  
5. Management  
5.1 Non-pharmacological interventions 
Non-pharmacological strategies constitute an approach that usually acts on modifiable 
risk factors, social engagement, cognitive training, and lifestyle interventions, 
including physical activity and diet/nutritional interventions.  
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Interventions focusing on specific risk factors have some uncertainties that need to be 
considered in the appraisal of the success of the intervention.  One important 
uncertainty is the still open questions about the real impact of their modification, as 
described above.  Also, risk factors are usually related, therefore interventions may 
usefully target multiple risk factors at once. For example, involvement in group-based 
exercise might increase physical activity and social engagement while helping to 
improve cardiovascular risk factors. 
Social interaction has been assayed in intervention studies, which have shown 
reduced risk of progression from mild to severe cognitive impairment associated with 
a greater frequency of engagement in social activities while mildly impaired (OR = 
0.72, 95% CI: 0.55–0.93, p = 0.01) [100]. In a recent meta-analysis, cognition-based 
intervention was associated with improved global cognitive function in people with 
MCI and weak evidence of improvements in the specific domains of executive 
function and delayed memory [101]. However, these types of intervention rely on the 
resources to implement and sustain them in practice, and the field has a need to 
develop evidence-based training which can be sustained by the individuals. In 
addition, evidence for the role of supportive environments is important. For example, 
support for active engagement or more general, long-term environmental support and 
accessible environments can enable social interaction, or a reduction of the demand of 
instrumental activities of daily living such as shopping. 
Physical activity is, as detailed above, a valuable modifiable risk to target. Despite the 
limitations of the available information, several meta-analyses of longitudinal studies 
are consistent in the value of physical activity as a risk reduction strategy for MCI 
[49,50].  Results, however, have been less clear when analyzing the limited number of 
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randomized controlled trials (RCTs). Recent meta-analyses have concluded that 
physical activity either improves global cognition with no specific effects on 
executive function and memory [101] or lacks consistent evidence of significant 
improvements [102] in people with MCI. 
Diet is a key factor to promoting brain health [103]. A meta-analysis of available 
prospective trials (n=5) found that a higher adherence to a Mediterranean-type diet is 
associated with a reduced risk of MCI and AD, as well as the progression from MCI 
to overt dementia [104]. Mediterranean diet could potentially exert neuroprotective 
effects via different mechanisms, such as reduction of inflammation and oxidative 
stress.  
In sum, non-pharmacological interventions may be associated with small cognitive 
benefits for people with MCI and currently its role can be considered as promising at 
best. Overall, the methodology of these studies needs further refinement. Most studies 
are underpowered, and lack of evidence of efficacy is not evidence of lack of efficacy 
[105]. In addition, consistency across studies is limited by the existence of several 
diagnostic criteria for MCI, which is a heterogeneous concept [102]. Results are also 
limited by the diversity of interventions and outcomes and short follow-up periods 
[105]. Further prospective studies with longer follow-up and high-quality RCTs are 
required to draw definitive conclusions. Future research should also test whether 
combination of these strategies (multimodal interventions) is associated with more 
benefits than monotherapy for MCI patients. 
5.2 Pharmacological interventions. 
There is a variety of interventions focusing on trials of medications, often those 
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prescribed to people diagnosed with dementias, or on management of co-morbidities.  
5.2.1 Against MCI 
There is no approved treatment for MCI. No drugs have so far shown evidence to 
reverse cognitive impairment [106]. However, given the heterogeneity of MCI, 
further studies testing different compounds in all subtypes of MCI are necessary to 
draw clear conclusions. However, the instability and spontaneous reversion to non-
MCI levels of cognition already mentioned (44% within a year) [14,18] adds 
difficulty to the interpretation of results. 
5.2.1.1 Acetylcholinesterase inhibitors  
Cholinergic deficits have been identified as a pathophysiological origin of AD, 
suggesting the use of acetylcholinesterase inhibitors to slow down the progression of 
MCI. Although one study [107] showed a positive significant effect of donepezil on 
cognition,  this  drug, widely used in AD,  has not demonstrated to be effective in 
decreasing the risk of progression from MCI to dementia over 1, 2 and 3 years[108] 
nor in having significant effect on cognition over the short term [109].  
Concerning galantamine, one study did not show a positive effect on cognition at 16 
weeks [110] and another [111] did not demonstrate benefits on the progression to 
dementia. Finally, a further study with rivastigmine [112] did not improve cognitive 
performance nor prevent conversion to dementia within 4 years. 
In addition, significant side effects may appear with the use of these compounds 
[108]. Hence, after reviewing all these data, there is no evidence to support the use of 
cholinesterase inhibitors in MCI [109], although the inclusion of patients on these 
trials with non AD-related aetiology could have biased or confounded these [113].  
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Furthermore, concerning acetylcholine related cognitive dysfunction, the loss of 
nicotinic receptors has been demonstrated in patients with AD, suggesting the 
possible benefits of nicotinic agonists on cognitive function of patients with MCI. 
Newhouse et al [114] provided evidence for nicotine-induced cognitive improvement 
in non smoking patients with amnestic MCI after 6 months of treatment with 
transdermal nicotine. Nevertheless larger studies are necessary to confirm this 
hypothesis. 
5.2.1.2 Other pharmacological interventions 
Oxidative stress has been associated with neuronal death in areas of the medial 
temporal lobe in patients with MCI or AD. The use of antioxidants can neutralize 
metabolic products which trigger neuronal injury and death via free radicals. These 
substances have been tested as possible cognitive enhancers in MCI and AD.  
The role of B vitamins has been assayed in several trials, but a recent meta-analysis 
reported only weak evidence of a beneficial effect on memory and a lack of adequate 
evidence of an effect on general cognitive function, executive function and attention 
in people with MCI [115]. One small double-blind study demonstrated that B 
vitamins appeared to slow cognitive and clinical decline in MCI patients with 
elevated homocysteine [116]. 
Ginkgo Biloba, widely used to enhance memory, was studied in a randomized, 
double-blind, placebo-controlled clinical trial of 3069 community-dwelling  older 
patients, failing to prevent cognitive decline in those with MCI or normal cognition 
[117], although positive effects have been reported in studies with smaller samples 
[118]. 
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The use of omega 3 fatty acids such as docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) is promising and studies [119] have shown an 
improvement in depressive symptoms and general function in patients with MCI, 
although further research is necessary to confirm these data and clarify their specific 
influence on cognition. 
Testosterone supplementation in men has been studied as a possible memory enhancer 
but the review of several studies suggests that this effect could only be detected in the 
short term and was restricted to men with low testosterone levels [120-122].  
Other compounds, like anti-inflammatory drugs, platelet aggregation inhibitors, or 
piracetam, have been investigated but the results have been inconclusive [123]. 
5.2.2 Against co-morbidities 
Advances in the treatment of comorbidities have been considered as an alternative 
option to improve outcomes. 
Antihypertensive drugs have been shown to help reduce the risk of developing 
dementia [124], and regular use of oxygen therapy for COPD patients decreases risk 
of cognitive decline (OR 0.14; 95% CI: 0.07–0.27; p < 0.0001) [125]. Thus additional 
healthcare support, medication review and monitoring may subsequently improve 
cognitive outcomes for these individuals. However, commonly prescribed 
medications such as statins which showed some benefits for cognitive decline in 
observational studies, failed to prove any significant effect in several large RCTs such 
as The PROSPER Study (PROspective study of pravastatin in the elderly at risk) 
[126].  
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Additionally, although patients with MCI and depression are suggested as being at 
more than twice the risk of developing AD than those without depression, the effect 
of treating depression has been very poorly investigated. One study found that those 
with depression at baseline seem to respond poorly to anti-depressant medication 
[127], while another study found that sertraline, a selective serotonin reuptake 
inhibitor (SSRI), improved performance on tests of attention, episodic memory, and 
executive function, but only in treatment responders [128]. 
This also suggests that behavioural intervention or lifestyle change that can improve 
psychological health could be particularly effective for this high-risk group. 
6. Conclusion 
MCI defines a clinical condition that is important because it identifies an intermediate 
state in the progression to dementia. The original clinical definition has been 
extended, although there is still doubt over whether it constitutes a clinical entity per 
se, or instead, it is only an early manifestation of an eventual dementia.  
Risk factors have been defined, and further research is needed to determine clearer 
indicators that will enable identification of factors that discriminate cases that will 
progress to dementia. Further research in the area of risk factors is also needed to 
identify the earliest predictors of impairment. This is because, encouragingly, many of 
the known risk factors are potentially modifiable, either through behavioural change, 
pharmaceutical intervention or promoting social engagement, and have already started 
to inform management and prevention strategies. How, and the extent to which such 
modifications delay progression of MCI is an important area for future clinical trials. 
Furthermore, emerging research methods, such as next generation genetic sequencing 
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and the ‘omics’ technologies, have the potential to characterise the biological 
underpinnings of cognitive decline in much greater detail, facilitating the 
development of novel therapeutics [129]. 
The debate on screening, including the potential for population screening, is crucial in 
the European-wide development of prevention and modification strategies. However, 
further research with improved screening is needed to determine the extent to which 
the currently observed instability of a diagnosis of MCI is indeed due to malleability 
of the condition or simply to imprecise assessment. The concept of providing 
evidence of change, or decline is central, as is the concomitant assessment of 
generally preserved independent functioning. The role of co-morbidities and 
medication should also be considered in a fuller screening, but in brief screenings, it 
is recommended that at least depression is screened for. Applications for everyday 
technology such as tablets and smart phones should make it possible for brief 
screenings to include assessments of processing speed or reaction times, and within 
task variability, both highlighted as highly predictive of potential decline in the 
literature, with clear links to neurobiological health. 
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